Updates on Dyslipidemia

Slides:



Advertisements
Similar presentations
ACC/AHA Guidelines Not the Final or Only Word. Contemporary Guidelines
Advertisements

Copyright © 2017 American Academy of Pediatrics.
Intensive Statin Recommendations
AIM HIGH Niacin plus Statin to prevent vascular events
PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.
The Latest Lipid Guidelines:
AIM-HIGH Niacin Plus Statin to Prevent Vascular Events
PCSK9 Inhibitors and Cardiovascular Outcomes Trials
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Statin Selection in the Elderly
Optimizing Statin Therapy
Current Dyslipidemia Management Guidelines Residual Risk.
An Endocrinology Clinic in Dyslipidemia
Diabetes and Dyslipidemia
A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.
Back to the Basics of Dyslipidemia
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
Cardiovascular Disease Risk Reduction Advances in Dyslipidemia
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Patient 1: 53-Year-Old Man With CVD Risk Factors
American Heart Association Scientific Sessions
Advances in Dyslipidemia: What Have We Learned From ACC 2017
Statins and the Elderly Patient
Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
Beyond Statin Therapy.
LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Statins and New-Onset Diabetes REAL Updates and Clinical Implications
Statin Class in Session
An Update on PCSK9 Inhibitors
Evaluating LDL-C Recommendations
New Pathways in Lipid Care
What's New in Dyslipidemia?
62-year-old Man With Unstable Angina
Statin Class in Session
Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.
Personalizing Statin Therapy in Patients With HIV
PCSK9 Inhibitors and Cardiovascular Outcomes
Overview. 5 Things You Need to Know About Statin Selection in Patients With HIV Infection.
PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?
A Patient Journey Through Statin Intolerance
Improving Appropriate Access to PCSK9 Inhibitors
Statins and HIV:.
New LDL-C Lipid Targets
Radical New Concepts in Lipid Management
Lipid Clinic Challenge
Clinicians' Corner in Dyslipidemia
Updates in Cardiovascular Medicine
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.
Préparation ESC Septembre
Glucose Management and Statin Therapy
LDL Cholesterol.
How to Optimize Cholesterol Management in High-Risk CV Patients
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Potential mechanisms whereby statins may reduce the risk of stroke
Lipid Updates From Spring 2019
New Lipid-Lowering Therapies
An Update on PCSK9 Inhibitors
Glucose Management and Statin Therapy
Lipids, the Heart, and the Kidney
Putting Your Skills to the Test
in diabetic patients with mixed dyslipidemia
PCSK9 Inhibitors and Real-World Evidence
ATP III Guidelines Drug Therapy FUTURE RESEARCH.
Shared-Decision Making in Dyslipidemia
Presentation transcript:

Updates on Dyslipidemia

Program Goals

Evidence For Drugs That Provide Additional LDL-C Lowering in Combination With Statins

Use of Lipid-Lowering Therapies in the Real World

Patient Case

Guidelines to Manage Dyslipidemia

Atorvastatin and Ezetimibe LDL-C Reduction

2017 Updated ACC Consensus Document on Role of Non-Statin Therapies for LDL-C Lowering

2017 ACC Focused Update Includes LDL-C and Non-HDL-C Thresholds

Empowering Patients to Take Charge of Lowering Their Lipids

Ezetimibe + Simvastatin: Stroke Prevention

Clinical Pearls

Abbreviations

Abbreviations (cont)